ADMA ADMA Biologics Inc

5.46
+0.4  (7.91%)
Previous Close 5.06
Open 5.18
Price To book 0.00
Market Cap 70.36M
Shares 12,886,000
Volume 157,277
Short Ratio 2.17
Av. Daily Volume 29,824

SEC filingsSee all SEC filings

  1. 8-K - Current report 17541533
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 161988779
  3. 8-K - Current report 161988501
  4. 8-K - Current report 161928373
  5. 8-K - Current report 161879317

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued July 29 2016. Third-party manufacturing issues cited.
RI-002
Primary Immune Deficiency Diseases

Latest News

  1. ADMA BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secu
  2. ADMA Biologics upgraded by Maxim Group
  3. 7:01 am ADMA Biologics announces transaction w/ Biotest Pharmaceuticals Corporation; co will acquire certain Biotest assets in exchange for shares of its common stock
  4. ADMA Biologics to Acquire Certain Assets from Biotest Pharmaceuticals Corporation and Become a Vertically Integrated Commercial Plasma Products Company
  5. ADMA Biologics Inc (ADMA): Does It Stack Up To Its Peers?
  6. ADMA: Incremental Progress on CMC Issue Resolution.
  7. ADMA BIOLOGICS, INC. Financials
  8. ETFs with exposure to ADMA Biologics, Inc. : November 16, 2016
  9. ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016
  10. ADMA BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
  11. ADMA Biologics Reports Third Quarter 2016 Results
  12. ADMA BIOLOGICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial S
  13. ETF’s with exposure to ADMA Biologics, Inc. : September 21, 2016
  14. ADMA BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  15. ADMA - Reviewing 2Q:16 Results; Waiting for Clarity on Resubmission Timeline
  16. ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 16, 2016
  17. ADMA BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
  18. ADMA BIOLOGICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  19. ADMA CRL Isolated to Partner Manufacturing Issues: Anticipate 8 Month Delay
  20. INVESTOR NOTICE: Goldberg Law PC Announces an Investigation of Claims against ADMA Biologics, Inc. and Advises Investors with Losses to Contact the Firm

SEC Filings

  1. 8-K - Current report 17541533
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 161988779
  3. 8-K - Current report 161988501
  4. 8-K - Current report 161928373
  5. 8-K - Current report 161879317
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 161828925
  7. 8-K - Current report 161828814
  8. 8-K - Current report 161808299
  9. 8-K - Current report 161709191
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 161649674